3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Vomiting
4
Nausea
3
Neoplasms
2
Solid Tumors
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Intestinal Obstruction
1
Hypopharyngeal Neoplasms
1
Critical Illness
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Sunitinib
4
Cyclophosphamide
4
Capecitabine
4
Bevacizumab
4
pazopanib
3
Topotecan
3
Paclitaxel
3
Docetaxel
3
Carboplatin
3
temsirolimus
2
liposomal doxorubicin
2
fludarabine
2
Sorafenib
2
Panobinostat
2
NVP-BKM120
2
Lapatinib
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Gemcitabine
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Bortezomib
2
vadimezan
1
spartalizumab
1
somatostatin receptor 2
1
selinexor
1
selicrelumab
1
perifosine
1
pegylated granulocyte colony-stimulating factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Solid Tumors
×
Metoclopramide
×
Clear all
NCT02135510
2020-03-31
MEDEA
Amsterdam UMC, location VUmc
Phase 3
Completed
249 enrolled